iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: http://link.springer.com/10.1007/BF00541922
Stereochemistry, a basis for sophisticated nonsense in pharmacokinetics and clinical pharmacology | European Journal of Clinical Pharmacology Skip to main content
Springer Nature Link
Log in

Stereochemistry, a basis for sophisticated nonsense in pharmacokinetics and clinical pharmacology

  • Special Article
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

The significance of stereochemistry in therapeutic action is outlined and elucidated. Often only one isomer is therapeutically active, but this does not mean that the other is really inactive. It may very well contribute to the side-effects. The therapeutically non-active isomer in a racemate should be regarded as an impurity (50% or more). It is emphasized how in clinical pharmacology, and particularly in pharmacokinetics, neglect of stereoselectivity in action leads to the performance of expensive “highly sophisticated scientific nonsense”. This also holds true in the development and marketing of new drugs as exemplified by various “pseudo-hybrid” drugs now reaching the clinic.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ariëns EJ, Simonis AM, van Rossum JM (1964) Drug-receptor interaction: interaction of one or more drugs with one receptor system. In: Ariëns EJ (ed) Molecular pharmacology, vol 1. Academic Press, New York London, pp 232–286

    Google Scholar 

  2. Ariëns EJ (1983) Stereoselectivity in bioactive agents: general aspects. In: Ariëns EJ, Soudijn W, Timmermans PBMWM (eds) Stereochemistry and biological activity of drugs. Blackwell Scientific Publications, Oxford London Edinburgh Boston Melbourne, pp 11–32

    Google Scholar 

  3. Lehmann F PA (1978) Stereoselective molecular recognition in biology. In: Cuatrecasas P, Greaves MF (eds) Receptors and recognition; vol 5, series A, Chapman and Hall, London, pp 1–77

    Google Scholar 

  4. Lehmann F PA, Rodrigues de Miranda JF, Ariëns EJ (1976) Stereoselectivity and affinity in molecular pharmacology. In: Jucker E (ed) Progress in drug research, vol 20. Birkhäuser, Basel Stuttgart, pp 101–142

    Google Scholar 

  5. Portoghese PS (1970) Relationships between stereostructure and pharmacological activities. In: Elliot HW, Cutting WC, Dreisbach RH (eds) Annual review of pharmacology, vol 10. Annual Reviews Inc, Palo Alto, CA, pp 51–76

    Google Scholar 

  6. Ariëns EJ, Simonis AM (1967) Cholinergic and anticholinergic drugs, do they act on common receptors? Ann NY Acad Sci 144: 842–868

    Google Scholar 

  7. Pfeiffer CC (1956) Optical isomerism and pharmacological action, a generalization. Science 124: 29–31

    Google Scholar 

  8. Ariëns EJ (1966) Eine Molekulargrundlage für die Wirkung von Pharmaka. I. Rezeptor-Theorie und Struktur-Wirkungs-Beziehung. Arzneimittelforsch 16: 1376–1393

    Google Scholar 

  9. Ooms AJJ, Boter HL (1965) Stereospecificity of hydrolytic enzymes in their reaction with optically active organophosphorus compounds-I. The reaction of cholinesterases and paraoxonase with S-alkyl p-nitrophenyl methylphosphonothiolates. Biochem Pharmacol 14: 1839–1846

    Google Scholar 

  10. Keeley FJ, Weiner DL, Okerholm RA (1983) Bioavailability of medroxalol in man. Biopharm Drug Dispos 4: 305–309

    Google Scholar 

  11. Wegler R, Eue L (1970) Herbizide. In: Wegler R (ed) Chemie der Pflanzenschutz- und Schädlingsbekämpfungsmittel. Band 2. Springer, Berlin Heidelberg New York, pp 172–395

    Google Scholar 

  12. Luckwill LC, Woodcock D (1956) In: Wain RL, Wightman F (eds) The chemistry and mode of action of plant growth substances. Butterworth London, p 195

    Google Scholar 

  13. Ney UM (1983) Enhancement of airway sensitivity to histamine in guinea-pigs by β-adrenoceptor blocking agents. Br J Pharmacol 78 [Proc Suppl]: 153 P

  14. Elliott HL, Meredith PA, Summer DJ, Reid JL (1984) Comparison of the clinical pharmacokinetics and concentration-effect relationships for medroxalol and labetalol. Br J Clin Pharmacol 17: 573–578

    Google Scholar 

  15. White PF, Ham J, Way WL, Trevor AJ (1980) Pharmacology of ketamine isomers in surgical patients. Anesthesiology 52: 231–239

    Google Scholar 

  16. Büch HP, Schneider-Affeld F, Rummel W (1973) Stereochemical dependence of pharmacological activity in a series of optically active N-methylated barbiturates. Naunyn-Schmiedeberg's Arch Pharmacol 277: 191–198

    Google Scholar 

  17. Downes H, Perry RS, Ostlund RE, Karler R (1970) A study of the excitatory effects of barbiturates. J Pharmacol Exp Ther 175: 692–699

    Google Scholar 

  18. Zimmerman DM, Gesellchen PD (1982) Analgesis (peripheral and central), endogenous opioids and their receptors. Ann Rep Med Chem 17: 21–30

    Google Scholar 

  19. Ariëns EJ (1963) Steric structure and activity of catecholamines on α- and β-receptors. In: Brunings KJ, Lindgren P (eds) Proceedings of the First International Pharmacological Meeting, vol 7. Pergamon Press, Oxford London New York Paris, pp 247–264

    Google Scholar 

  20. Ariëns EJ (1967) The structure-activity relationships of beta adrenergic drugs and beta adrenergic blocking drugs. Ann NY Acad Sci 139: 606–631

    Google Scholar 

  21. Lotti VJ, Taylor DA (1982) α2-Adrenergic agonist and antagonist activity of the respective (−)- and (+)-enantiomers of 6-ethyl-9-oxaergoline (EOE). Eur J Pharmacol 85: 211–215

    Google Scholar 

  22. Smith MS, Wain RL, Wightman F (1952) Studies on plant growth-regulating substances. V. Steric factors in relation to mode of action of certain aryloxyalkylcarboxylic acids. Ann Appl Biol 39: 295–307

    Google Scholar 

  23. Tobert JA, Cirillo VJ, Hitzenberger G, James I, Pryor J, Cook T, Buntinx A, Holmes IB, Lutterbeck PM (1981) Enhancement of uricosuric properties of indacrinone by manipulation of the enantiomer ratio. Clin Pharmacol Ther 29: 344–350

    Google Scholar 

  24. Hoffman WF, Woltersdorf OW Jr, Novello FC, Cragoe Jr EJ (1981) (Acylaryloxy) acetic acid diuretics. 3. 2,3-Dihydro-5-acyl-2-benzofurancarboxylic acids, a new class of uricosuric diuretics. J Med Chem 24: 865–873

    Google Scholar 

  25. Kaiser DG, van Geissen GJ, Reisher RJ, Wechter WJ (1976) Isomeric inversion of ibuprofen (R)-enantiomer in humans. J Pharm Sci 65: 269–273

    Google Scholar 

  26. Hutt AJ, Caldwell J (1983) The metabolic chiral inversion of 2-arylpropionic acids — a novel route with pharmacological consequences. J Pharm Pharmacol 35: 693–704

    Google Scholar 

  27. Ariëns EJ (1971) A general introduction to the field of drug design. In: Ariëns EJ (ed) Drug design, vol 1. Academic Press, New York London, pp 34–35

    Google Scholar 

  28. Low LK, Castagnoli N Jr (1978) Enantioselectivity in drug metabolism. In: Clarke FH (ed) Annual reports in medicinal chemistry, vol 13. Academic Press, New York London, pp 304–315

    Google Scholar 

  29. Jenner P, Testa B (1973) The influence of stereochemical factors on drug disposition. Drug Metab Rev 2[2]: 117–184

    Google Scholar 

  30. Vermeulen NPE, Breimer DD (1983) Stereoselectivity in drug and xenobiotic metabolism. In: Ariëns EJ, Soudijn W, Timmermans PBMWM (eds) Stereochemistry and biological activity of drugs. Blackwell, Oxford London Edinburgh Boston Melbourne, pp 33–53

    Google Scholar 

  31. Walle T, Wilson MJ, Walle UK, Bai SA (1983) Stereochemical composition of propranolol metabolites in the dog using stable isotope-labeled pseudoracemates. Drug Metab Dispos 11: 544–549

    Google Scholar 

  32. Patil PN, Miller DD, Trendelenburg U (1975) Molecular geometry and adrenergic drug activity. Pharmacol Rev 26: 323–392

    Google Scholar 

  33. Van Ginneken CAM, Rodrigues de Miranda JF, Beld AJ (1983) Stereoselectivity and drug distribution. In: Ariëns EJ, Soudijn W, Timmermans PBMWM (eds) Stereochemistry and biological activity of drugs. Blackwell, Oxford London Edinburgh Boston Melbourne, pp 55–62

    Google Scholar 

  34. Koopman PC (1960) Neurotransmitters and their chemical derivatives. PhD Thesis University of Nijmegen, Bronder-Offset, Rotterdam, pp 1–112

    Google Scholar 

  35. Ariëns EJ, Waelen MJGA, Sonneville PF, Simonis AM (1963) The pharmacology of catecholamines and their derivatives. I. Arzneimittelforsch 13: 541–546

    Google Scholar 

  36. Waelen MJGA (1963) Vaatverwijdende middelen. MD Thesis University of Nijmegen, Thoben Offset, Nijmegen, pp 1–186

    Google Scholar 

  37. Ariëns EJ (1967) Wirkung und Wirkungsmechanismus von Katecholaminen und ihren Derivaten. Naunyn-Schmiedeberg's Arch Pharmacol Exp Pathol 257: 118–141

    Google Scholar 

  38. Brittain RT, Drew GM, Levy GP (1982) The α-and β-adrenoceptor blocking potencies of labetalol and its individual stereoisomers in anaesthetized dogs and in isolated tissues. Br J Pharmacol 77: 105–114

    Google Scholar 

  39. Spedding M (1981) Partial agonist effects of medroxalol at β2-adrenoceptors. Br J Pharmacol 74: 847P-848P

    Google Scholar 

  40. Gold EH, Chang W, Cohen M, Baum T, Ehrreich S, Johnson G, Prioli N, Sybertz EJ (1982) Synthesis and comparison of some cardiovascular properties of the stereoisomers of labetalol. J Med Chem 25: 1363–1370

    Google Scholar 

  41. Sybertz EJ, Sabin CS, Pula KK, Vander Vliet G, Glennon J, Gold EH, Baum T (1981) Alpha- and beta-adrenoceptor blocking properties of labetalol and its R, R-isomer, SCH 19927. J Pharmacol Exp Ther 218: 435–443

    Google Scholar 

  42. Baum T, Watkins RW, Sybertz EJ, Vemulapalli S, Pula KK, Eynon E, Nelson S, Vander Vliet G, Glennon J, Moran RM (1981) Antihypertensive and hemodynamic actions of SCH 19927, the R, R-isomer of labetalol. J Pharmacol Exp Ther 218: 444–452

    Google Scholar 

  43. Ariëns EJ (1983) Stereochemie en bioactiviteit. Chem Magazine, October, 545–548

  44. Cheng HC, Reavis OK Jr, Grisar JM, Claxton GP, Weiner DL, Woodward JK (1980) Antihypertensive and adrenergic receptor blocking properties of the enantiomers of medroxalol. Life Sci 27: 2529–2534

    Google Scholar 

  45. Eden RJ, Owen DAA, Taylor EM (1983) The pharmacology of the two stereoisomers of prizidilol. Br J Pharmacol 78 [Proc Suppl]: 34P

  46. Snell ES (1982) Pharmacological appraisal of fixed-dose combination medicines: discussion paper. J Roy Soc Med 75: 457–463

    Google Scholar 

  47. Shenfield GM (1982) Fixed combination drug therapy. Drugs 23: 462–480

    Google Scholar 

  48. Wijnberg H (1980) Synthesis devised for asymmetric compounds. Chem Eng News 58: 24 (September 1980)

    Google Scholar 

  49. Mosher HS, Morrison JD (1983) Current status of asymmetric synthesis. Science 221: 1013–1019

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Pharmacology, University of Nijmegen, Geert Grooteplein Noord 21, 6525 EZ, Nijmegen, The Netherlands

    E. J. Ariëns

Authors
  1. E. J. Ariëns
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ariëns, E.J. Stereochemistry, a basis for sophisticated nonsense in pharmacokinetics and clinical pharmacology. Eur J Clin Pharmacol 26, 663–668 (1984). https://doi.org/10.1007/BF00541922

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00541922

Key words

Search

Navigation